title: How We Treat Myeloproliferative Neoplasms.
abstract: The present report focuses on management strategies for the myeloproliferative neoplasm according to the structure and processes we use within our center, a large tertiary unit in central London. The standard procedures for achieving an accurate diagnosis and risk stratification and therapeutic strategies for these diseases with a detailed focus on contentious areas are discussed. In the 9 years after the description of the Janus kinase 2 mutation, this field has altered quite radically in several aspects. For example, a new therapeutic paradigm exists, especially for myelofibrosis. We share how our unit has adapted to these changes.
authors: Department of Haematology, Guy's and St. Thomas' National Health Service Foundation Trust, London, United Kingdom. Electronic address: Claire.Harrison@gstt.nhs.uk.
authors: Claire N
authors: CN
authors: Harrison
authors: Department of Haematology, Guy's and St. Thomas' National Health Service Foundation Trust, London, United Kingdom.
authors: Donal P
authors: DP
authors: McLornan
authors: Department of Haematology, Guy's and St. Thomas' National Health Service Foundation Trust, London, United Kingdom.
authors: Yvonne A
authors: YA
authors: Francis
authors: Department of Haematology, Guy's and St. Thomas' National Health Service Foundation Trust, London, United Kingdom.
authors: Claire
authors: C
authors: Woodley
authors: Pharmacy Service, Guy's and St. Thomas' National Health Service Foundation Trust, London, United Kingdom.
authors: Lizzie
authors: L
authors: Provis
authors: Department of Haematology, Guy's and St. Thomas' National Health Service Foundation Trust, London, United Kingdom.
authors: Deepti H
authors: DH
authors: Radia
mesh_terms: D006801:Humans; D009196:Myeloproliferative Disorders / Q000235:genetics / Q000628:therapy*
keywords: Erythrocytosis; Myelofibrosis; Polycythemia; Thrombocythemia; Thrombocytosis